Recent developments in anti-rheumatic drugs in pediatrics: Treatment of juvenile idiopathic arthritis

Arthritis Research and Therapy

Volumn 11, Issue 1, 2009, Pages

  Hayward, Kristen ^a   Wallace, Carol A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACZ 885; ADALIMUMAB; ANTIRHEUMATIC AGENT; ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LEFLUNOMIDE; LENALIDOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALLERGIC REACTION; ALOPECIA; ANOREXIA; ANTIBODY PRODUCTION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CYTOKINE PRODUCTION; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; HYPOPHOSPHATEMIA; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION RISK; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; LYMPHOMA; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SERUM SICKNESS; SIDE EFFECT; SOMNOLENCE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; CHILD;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 69249203713     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2619     Document Type: Review

References (52)

1. Helmick CG Felson DT Lawrence RC Gabriel S Hirsch R Kwoh CK Liang MH Kremers HM Mayes MD Merkel PA Pillemer SR Reveille JD Stone JH National Arthritis Data Workgroup Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I Arthritis Rheum 2008, 58:15-25. 10.1002/art.23177 18163481
2. Petty RE Southwood TR Manners P Baum J Glass DN Goldenberg J He X Maldonado-Cocco J Orozco-Alcala J Prieur AM Suarez-Almazor ME Woo P International League of Associations for Rheumatology International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001 J Rheumatol 2004, 31:390-392. 14760812
3. Minden K Kiessling U Listing J Niewerth M Doring E Meincke J Schontube M Zink A Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy J Rheumatol 2000, 27:2256-2263. 10990244
4. Packham JC Hall MA Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Functional outcome Rheumatology (Oxford) 2002, 41:1428-1435. 10.1093/rheumatology/41.12.1428 12468825
5. Wallace CA Huang B Bandeira M Ravelli A Giannini EH Patterns of clinical remission in select categories of juvenile idiopathic arthritis Arthritis Rheum 2005, 52:3554-3562. 10.1002/art.21389 16255044
6. Haines KA Juvenile idiopathic arthritis: Therapies in the 21st century Bull NYU Hosp Jt Dis 2007, 65:205-211. 17922671
7. Hashkes PJ Laxer RM Medical treatment of juvenile idiopathic arthritis JAMA 2005, 294:1671-1684. 10.1001/jama.294.13.1671 16204667
8. Wallace CA Current management of juvenile idiopathic arthritis Best Pract Res Clin Rheumatol 2006, 20:279-300. 10.1016/j.berh.2005.11.008 16546057
9. Ringold S Wallace CA Measuring clinical response and remission in juvenile idiopathic arthritis Curr Opin Rheumatol 2007, 19:471-476. 10.1097/BOR.0b013e32825a6a68 17762613
10. Kutukculer N Caglayan S Aydogdu F Study of pro-inflammatory (TNF-α, IL-1α, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: Correlations with clinical and laboratory parameters Clin Rheumatol 1998, 17:288-292. 10.1007/BF01451007 9776110
11. Lovell DJ Giannini EH Reiff A Cawkwell GD Silverman ED Nocton JJ Stein LD Gedalia A Ilowite NT Wallace CA Whitmore J Finck BK Etanercept in children with polyarticular juvenile rheumatoid arthritis. pediatric rheumatology collaborative study group N Engl J Med 2000, 342:763-769. 10.1056/NEJM200003163421103 10717011
12. Lovell DJ Reiff A Ilowite NT Wallace CA Chon Y Lin SL Baumgartner SW Giannini EH Pediatric Rheumatology Collaborative Study Group Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis Arthritis Rheum 2008, 58:1496-1504. 10.1002/art.23427 18438876
13. Horneff G De Bock F Foeldvari I Girschick HJ Michels H Moebius D Schmeling H Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA registry Ann Rheum Dis 2008. 18413440
14. Prince FH Twilt M Ten Cate R van Rossum MA Armbrust W Hoppenreijs EP van Santen-Hoeufft M Koopman-Keernink Y Wulffraat NM van Suijlekom-Smit LW Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register Ann Rheum Dis 2008. 18413443
15. Ruperto N Lovell DJ Cuttica R Wilkinson N Woo P Espada G Wouters C Silverman ED Balogh Z Henrickson M Apaz MT Baildam E Fasth A Gerloni V Lahdenne P Prieur AM Ravelli A Saurenmann RK Gamir ML Wulffraat N Marodi L Petty RE Joos R Zulian F McCurdy D Myones BL Nagy K Reuman P Szer I Travers S Beutler A Keenan G Clark J Visvanathan S Fasanmade A Raychaudhuri A Mendelsohn A Martini A Giannini EH Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis Arthritis Rheum 2007, 56:3096-3106. 10.1002/art.22838 17763439
16. Laken van der CJ Voskuyl AE Roos JC Stigter van Walsum M de Groot ER Wolbink G Dijkmans BA Aarden LA Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis Ann Rheum Dis 2007, 66:253-256. 10.1136/ard.2006.057406 16793840
17. Gerloni V Pontikaki I Gattinara M Fantini F Focus on adverse events of TNFα blockade in JIA in an open monocentric long-term prospective study of 163 patients Ann Rheum Dis 2008, 67:1145-1152. 10.1136/ ard.2007.069484 17981916
18. Lovell DJ Ruperto N Goodman S Reiff A Jung L Jarosova K Nemcova D Mouy R Sandborg C Bohnsack J Elewaut D Foeldvari I Gerloni V Rovensky J Minden K Vehe RK Weiner LW Horneff G Huppertz HI Olson NY Medich JR Carcereri-De-Prati R McIlraith MJ Giannini EH Martini A Pediatric Rheumatology Collaborative Study Group, Pediatric Rheumatology International Trials Organisation Adalimumab with or without methotrexate in juvenile rheumatoid arthritis N Engl J Med 2008, 359:810-820. 10.1056/NEJMoa0706290 18716298
19. Kanakoudi-Tsakalidou F Tzimouli V Pratsidou-Gertsi P Chronopoulou E Trachana M The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment Cytokine 2008, 42:293-297. 10.1016/j.cyto.2008.01.007 18445529
20. Giannini E Ilowite N Lovell D Wallace C Rabinovich C Reiff A Higgins G Gottlieb B Chon Y Lin S-L The long-term safety of etanercept (Enbrel®) in children with polyarticular or systemic juvenile rheumatoid arthritis. Interim results of a 3-year, open-label registry [oral presentation] ACR Keystone Pediatric Rheumatology Symposium Keystone 2008.
21. Ilowite N Porras O Reiff A Rudge S Punaro M Martin A Allen R Harville T Sun YN Bevirt T Aras G Appleton B Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter study Clin Rheumatol 2009, 28:129-137. 10.1007/s10067-008-0995-9 18766426
22. Pascual V Allantaz F Arce E Punaro M Banchereau J Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade J Exp Med 2005, 201:1479-1486. 2213182 15851489 10.1084/jem.20050473
23. Lequerre T Quartier P Rosellini D Alaoui F De Bandt M Mejjad O Kone-Paut I Michel M Dernis E Khellaf M Limal N Job-Deslandre C Fautrel B Le Loet X Sibilia J Societe Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pediatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: Preliminary experience in France Ann Rheum Dis 2008, 67:302-308. 10.1136/ard.2007.076034 17947302
24. Gattorno M Piccini A Lasiglie D Tassi S Brisca G Carta S Delfino L Ferlito F Pelagatti MA Caroli F Buoncompagni A Viola S Loy A Sironi M Vecchi A Ravelli A Martini A Rubartelli A The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis Arthritis Rheum 2008, 58:1505-1515. 10.1002/art.23437 18438814
25. Lovell DJ Giannini EH Kimura Y Li S Hashkes PJ Reiff AO Wallace CA Onel KB Wei Y Fury W Nadler DR Biedermann S Osgood G Papadopoulos JH Radin AR Preliminary evidence for sustained bioactivity of IL-1 trap (rilonacept), A long acting IL-1 inhibitor, in systemic onset juvenile idiopathic arthritis (SJIA) [abstract] Arthritis Rheum 2007, 56:S514.
26. Sho M Yamada A Najafian N Salama AD Harada H Sandner SE Sanchez-Fueyo A Zheng XX Strom TB Sayegh MH Physiological mechanisms of regulating alloimmunity: Cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size J Immunol 2002, 169:3744-3751. 12244168
27. Ruperto N Lovell DJ Quartier P Paz E Rubio-Perez N Silva CA Abud-Mendoza C Burgos-Vargas R Gerloni V Melo-Gomes JA Saad-Magalhaes C Sztajnbok F Goldenstein-Schainberg C Scheinberg M Penades IC Fischbach M Orozco J Hashkes PJ Hom C Jung L Lepore L Oliveira S Wallace CA Sigal LH Block AJ Covucci A Martini A Giannini EH Paediatric Rheumatology INternational Trials Organization, Pediatric Rheumatology Collaborative Study Group Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial Lancet 2008, 372:383-391. 10.1016/S0140-6736(08)60998-8 18632147
28. Emery P Fleischmann R Filipowicz-Sosnowska A Schechtman J Szczepanski L Kavanaugh A Racewicz AJ van Vollenhoven RF Li NF Agarwal S Hessey EW Shaw TM DANCER Study Group The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum 2006, 54:1390-1400. 10.1002/art.21778 16649186
29. El-Hallak M Binstadt BA Leichtner AM Bennett CM Neufeld EJ Fuhlbrigge RC Zurakowski D Sundel RP Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases J Pediatr 2007, 150:376-382. 10.1016/j.jpeds.2006.10.067 17382113
30. Keystone EC Emery P Peterfy CG Tak PP Cohen S Genovese MC Dougados M Burmester GR Greenwald M Kvien TK Williams S Hagerty D Cravets MW Shaw T Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies Ann Rheum Dis 2009, 68:216-221. 10.1136/ard.2007.085787 18388156
31. McGonagle D Tan AL Madden J Taylor L Emery P Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis Rheumatology (Oxford) 2008, 47:865-867. 10.1093/rheumatology/ken103 18390581
32. Cohen SB Emery P Greenwald MW Dougados M Furie RA Genovese MC Keystone EC Loveless JE Burmester GR Cravets MW Hessey EW Shaw T Totoritis MC REFLEX Trial Group Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 2006, 54:2793-2806. 10.1002/art.22025 16947627
33. Kuek A Hazleman BL Gaston JH Ostor AJ Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab Rheumatology (Oxford) 2006, 45:1448-1449. 10.1093/rheumatology/kel301 16920752
34. Bennett CM Rogers ZR Kinnamon DD Bussel JB Mahoney DH Abshire TC Sawaf H Moore TB Loh ML Glader BE McCarthy MC Mueller BU Olson TA Lorenzana AN Mentzer WC Buchanan GR Feldman HA Neufeld EJ Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura Blood 2006, 107:2639-2642. 1895391 16352811 10.1182/ blood-2005-08-3518
35. Rao A Kelly M Musselman M Ramadas J Wilson D Grossman W Shenoy S Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias Pediatr Blood Cancer 2008, 50:822-825. 10.1002/pbc.21264 17570702
36. Yilmaz M Kendirli SG Altintas D Bingol G Antmen B Cytokine levels in serum of patients with juvenile rheumatoid arthritis Clin Rheumatol 2001, 20:30-35. 10.1007/s100670170100 11254238
37. Yokota S Imagawa T Mori M Miyamae T Aihara Y Takei S Iwata N Umebayashi H Murata T Miyoshi M Tomiita M Nishimoto N Kishimoto T Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal phase III trial Lancet 2008, 371:998-1006. 10.1016/ S0140-6736(08)60454-7 18358927
38. Genovese MC McKay JD Nasonov EL Mysler EF da Silva NA Alecock E Woodworth T Gomez-Reino JJ Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 2008, 58:2968-2980. 10.1002/art.23940 18821691
39. van Roon EN Hoekstra M Tobi H Jansen TL Bernelot Moens HJ Brouwers JR Laar van de MA Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation Br J Clin Pharmacol 2005, 60:319-325. 1884775 16120072 10.1111/j.1365-2125.2005.02430.x
40. Kaltwasser JP Behrens F Leflunomide: Long-term clinical experience and new uses Expert Opin Pharmacother 2005, 6:787-801. 10.1517/ 14656566.6.5.787 15934905
41. Silverman E Mouy R Spiegel L Jung LK Saurenmann RK Lahdenne P Horneff G Calvo I Szer IS Simpson K Stewart JA Strand V Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group Leflunomide or methotrexate for juvenile rheumatoid arthritis N Engl J Med 2005, 352:1655-1666. 10.1056/NEJMoa041810 15843668
42. Vallet S Palumbo A Raje N Boccadoro M Anderson KC Thalidomide and lenalidomide: Mechanism-based potential drug combinations Leuk Lymphoma 2008, 49:1238-1245. 10.1080/10428190802005191 18452080
43. Garcia-Carrasco M Fuentes-Alexandro S Escarcega RO Rojas-Rodriguez J Escobar LE Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis Joint Bone Spine 2007, 74:500-503. 10.1016/ j.jbspin.2006.12.004 17706449
44. Lehman TJ Schechter SJ Sundel RP Oliveira SK Huttenlocher A Onel KB Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study J Pediatr 2004, 145:856-857. 10.1016/ j.jpeds.2004.08.020 15580219
45. Chanan-Khan AA Cheson BD Lenalidomide for the treatment of B-cell malignancies J Clin Oncol 2008, 26:1544-1552. 10.1200/JCO.2007.14.5367 18285605
46. De Kleer IM Brinkman DM Ferster A Abinun M Quartier P Net Van Der J Ten Cate R Wedderburn LR Horneff G Oppermann J Zintl F Foster HE Prieur AM Fasth A Van Rossum MA Kuis W Wulffraat NM Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: Analysis of clinical effects, mortality, and transplant related morbidity Ann Rheum Dis 2004, 63:1318-1326. 1754760 15361393 10.1136/ard.2003.017798
47. Brinkman DM de Kleer IM ten Cate R van Rossum MA Bekkering WP Fasth A van Tol MJ Kuis W Wulffraat NM Vossen JM Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: Long-term follow-up of a prospective clinical trial Arthritis Rheum 2007, 56:2410-2421. 10.1002/ art.22656 17599770
48. Raza K Buckley CE Salmon M Buckley CD Treating very early rheumatoid arthritis Best Pract Res Clin Rheumatol 2006, 20:849-863. 10.1016/ j.berh.2006.05.005 16980210
49. van Rossum MA van Soesbergen RM Boers M Zwinderman AH Fiselier TJ Franssen MJ ten Cate R van Suijlekom-Smit LW Wulffraat NM van Luijk WH Oostveen JC Kuis W Dijkmans BA Dutch Juvenile Idiopathic Arthritis Study group Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: Sustained benefits of early sulfasalazine treatment Ann Rheum Dis 2007, 66:1518-1524. 10.1136/ard.2006.064717 17491099
50. Giannini EH Ruperto N Ravelli A Lovell DJ Felson DT Martini A Preliminary definition of improvement in juvenile arthritis Arthritis Rheum 1997, 40:1202-1209. 9214419
51. Brunner HI Lovell DJ Finck BK Giannini EH Preliminary definition of disease flare in juvenile rheumatoid arthritis J Rheumatol 2002, 29:1058-1064. 12022323
52. Wallace CA Ruperto N Giannini E Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis J Rheumatol 2004, 31:2290-2294. 15517647